An Agenda: Avian Influenza Economics
Essentially all public health officials agree that an avian flu pandemic is just over the horizon. Governments around the world are bracing for a very serious event, one on the order of the 1918 pandemic that killed at least 40 million and perhaps as many as 120 million people.
Such a pandemic would be the defining event for a generation, yet it would be strangely different from past defining events:
What you can expect to find here is a critical commentary on the events that lead us toward, through, and past the anticipated avian flu pandemic. The issues that you can expect to see discussed here include:
Such a pandemic would be the defining event for a generation, yet it would be strangely different from past defining events:
- First, the stages of this pandemic --- unlike wars or other human disaster --- are reasonably amenable to being thought through well in advance of the events themselves.
- Second, although there will be innumerable surprises, we know that the event will be of limited duration.
- Third, with high probability (and with perhaps a few small exceptions), the permanent changes will be personal and local --- not geo-political.
What you can expect to find here is a critical commentary on the events that lead us toward, through, and past the anticipated avian flu pandemic. The issues that you can expect to see discussed here include:
- The economics and the ethics of antiviral (Tamiflu, Relenza) stockpiling by governments, NGOs, business enterprises, and individuals.
- The responses of financial markets to the present pandemic threat --- including contrasts with past pandemics and pandemic threats (SARS).
- The responses of pharmaceutical firms to the approaching pandemic, including changes in patent policy such as Roche's non-statement statement that "Tamiflu is not protected by patent in Indonesia."
0 Comments:
Post a Comment
<< Home